Abstract:Marcus Sim, 1 Anthony Yii, 1 Xiaomeng Xu, 2 Priti Bahety, 3 Chee Hong Loh, 1 Aldo Amador Navarro Rojas, 4 Dominique Milea, 2 Augustine Tee 1 1 Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore, Singapore; 2 Value Evidence & Outcomes, Greater China and Intercontinental, GSK, Singapore, Singapore; 3 Medical Affairs, GSK, Singapore, Singapore; 4 Respiratory & Specialty Medical Lead, Greater China and Intercontinental, GSK, Singapore, Singapore Correspondence: Marcus Sim, Department of Respiratory and Critical Care Medicine, Changi General Hospital, 2 Simei Street 3, Singapore, 529889, Singapore, Tel +65 6788 8833, Email Introduction: There is limited real-world evidence regarding clinical practice for chronic obstructive pulmonary disease (COPD) in Singapore. We compared baseline clinical characteristics and evaluated outcomes in patients with COPD who initiated treatment with either a long-acting muscarinic antagonist (LAMA) or a LAMA and a long-acting β 2 -agonist (LAMA+LABA). Methods: This was a single-center observational study at Changi General Hospital, Singapore. Routine clinical data (hospital visits, case management, lung function, laboratory/imaging results, medication orders) were collected and compiled into a data warehouse. Eligible patients with COPD were ≥ 40 years old and newly prescribed LAMA or LAMA+LABA during the enrollment period. Patient characteristics in the baseline period (6 months) were compared between treatments. Clinical worsening was measured as a composite endpoint, defined as the first of a change in maintenance treatment class or a moderate-to-severe exacerbation during follow-up (12 months). Results: In total, 261 patients were included in the baseline period (LAMA: 73; LAMA+LABA: 188). In the baseline period, patients receiving LAMA+LABA versus LAMA had significantly lower body mass index, higher COPD Assessment Test score and worse lung function, and numerically higher exacerbation history. Prevalence of comorbidities was similar between treatment groups. In follow-up, high rates of clinical worsening were observed regardless of treatment regimen (LAMA: 38/73 [52%]; LAMA+LABA: 86/188 [46%]). Median time-to-clinical worsening was 340 days for the LAMA cohort and the raw median 154 days (interquartile range: 44– 225) for the LAMA+LABA cohort. Median medication dispensation rate (0.86; interquartile range: 0.56– 1.00) was similar between treatments. Conclusion: Patients initiating treatment with LAMA+LABA had more severe COPD than patients prescribed LAMA. The proportion of patients experiencing clinical worsening was similarly high in both cohorts, suggesting that early identification and treatment optimization are necessary. Keywords: COPD treatment, database analysis, dual bronchodilator, LABA, LAMA, inhaler prescription Why was the study done? Guidelines for the treatment of patients with chronic obstructive pulmonary disease (COPD) are largely based on the results of clinical trials. However, clinical practice can be influenced by factors that are not taken into consideration in clinical trials. This leads to a gap between clinical practice and treatment guidelines. Some guidelines recommend starting treatment with a long-acting muscarinic antagonist (LAMA) medication only, while others recommend starting treatment with a combination of a LAMA and a long-acting β 2 -agonist medication (LAMA+LABA). More studies with real-world data are needed to address the gap between clinical practice and treatment guidelines. What did the researchers do and find? We collected clinical data, including inpatient and emergency department visits, from patients with COPD in a hospital in Singapore. Data were collected for 1 year after patients started treatment with either LAMA or LAMA+LABA. We generated a data warehouse and used it to compare the clinical characteristics of patients with COPD who had started treatment with LAMA or LAMA+LABA. Before they started treatment, patients who were prescribed LAMA+LABA had worse lung function, symptoms and health status than those who were prescribed LAMA. Approximately half of patients experienced health decline, regardless of their treatment regimen. What do these results mean? The results of this study indicate that patients starting treatment with LAMA+LABA have more severe COPD than those starting LAMA alone. However, many patients in both treatment groups experienced health decline, highlighting the need for early identification to ensure patients receive optimal treatment. Chronic obstructive pulmonary disease (COPD) represents a substantial health burden and is currently th -Abstract Truncated-

SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study

SABA prescriptions and asthma management practices in patients treated by specialists in Taiwan: Results from the SABINA III study

Short-acting Beta-2 Agonist Prescription Patterns and Clinical Outcomes in Chinese Patients with Asthma: an Observational Study in Mainland China for the SABINA Programme

Overprescription of short-acting β 2 agonists: reflections from the SABINA study in Brazil

Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

SABINA + Hong Kong: a territory wide study of prescribing trends and outcomes associated with the use of short-acting β2 agonists in the Chinese population

Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population

National expert consensus on short-acting beta2-agonist overreliance in asthma care in Malaysia

The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia

Short-acting β2-agonists (SABA) overuse in asthma and patients' perceptions for this behavior

Asthma prescribing and reattendance in Emergency Care in a London District Hospital

Asthma: effect of excess short-acting {beta}2-agonist (SABA) inhaler prescriptions on healthcare resource utilisation

Over-the-counter short-acting β 2 -agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study

The Burden of Short-Acting β2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program

Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study

Association of quality-of-care indicators with asthma outcomes: A retrospective observational study for asthma care in Singapore

Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis

Evaluating the Feasibility of a Community Pharmacy-Delivered Behaviour Change Intervention to Reduce Reliever Reliance in Asthma

Characteristics of Patients with Chronic Obstructive Pulmonary Disease Treated with Long-Acting Bronchodilators in a Real-World Setting in Singapore: A Single-Center Observational Study

Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia

Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate